Welcome to our dedicated page for Artivion SEC filings (Ticker: AORT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Artivion, Inc. (NYSE: AORT), a medical device company focused on cardiac and vascular surgery and the treatment of aortic diseases. Through these filings, investors can review Artivion’s detailed financial statements, risk disclosures, material agreements and governance information.
Artivion’s periodic reports on Forms 10-K and 10-Q describe its business, which includes aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vascular human tissues, as well as preservation services for cardiac and vascular tissues. These filings outline segment-level information, geographic reach and key risk factors associated with its aortic-focused product portfolio and international operations.
Current reports on Form 8-K document material events such as quarterly financial results, amendments to the company’s credit and guaranty agreement, real estate purchase contracts for manufacturing and office facilities, and executive leadership changes. For example, recent 8-K filings discuss an amendment that extended the maturity of term loan and revolving credit facilities and added a secured delayed draw term loan facility, as well as agreements to purchase properties supporting On-X manufacturing operations in Austin, Texas.
On Stock Titan, Artivion’s SEC filings are updated in near real time as they are posted to EDGAR. AI-powered summaries help explain complex sections of lengthy documents, such as credit agreement amendments, non-GAAP reconciliations, and detailed risk factor discussions. Investors can quickly locate annual reports (Form 10-K), quarterly reports (Form 10-Q), and current reports (Form 8-K), and use AI-generated highlights to understand how new filings may relate to Artivion’s aortic device portfolio, clinical programs, capital structure and corporate strategy.
Artivion, Inc. (AORT) insider transaction: SVP and General Counsel Jean F. Holloway reported the sale of 5,761 shares of common stock at $45.858 on 11/13/2025. The filing states the shares were sold upon the vesting of restricted stock units to pay tax withholding obligations via a “sell to cover” and “does not represent a discretionary transaction.”
Following the sale, the reporting person beneficially owns 163,408 shares directly. This Form 4 reflects an administrative tax-related sale rather than an open‑market discretionary trade.
Artivion (AORT) insider transaction: Officer Marshall Stanton reported a sell-to-cover of 4,993 shares of common stock at $45.858 on 11/13/2025. The filing states the shares were sold upon RSU vesting to satisfy tax withholding obligations and did not represent a discretionary transaction.
Following the transaction, Stanton beneficially owns 56,641 shares directly. His role is listed as SVP, Clinical & MD Affair, and the filing was made by one reporting person.
AORT: A holder filed a Form 144 notice to sell 6,393 shares of common stock through Fidelity Brokerage Services, with an aggregate market value $285,575.31. The filing lists an approximate sale date of 11/14/2025 on the NYSE. Shares outstanding were 47,374,939.
The shares to be sold were acquired on 11/14/2025 via an option originally granted on 03/05/2019, with payment noted as cash. The filing also reports past 3‑month sales by John E. Davis: 3,373 shares on 11/10/2025 for $150,499.55 and 6,563 shares on 11/13/2025 for $300,968.02.
AORT received a Form 144 notice covering a proposed sale of 3,482 common shares. The filing lists an aggregate market value of $159,678.60, with an approximate sale date of 11/13/2025 on the NYSE through Fidelity Brokerage Services LLC.
The shares were acquired via restricted stock vesting on 11/10/2025 and 11/11/2025 in two equal tranches of 1,741 shares each, characterized as compensation. The filing also reports that Amy D. Horton sold 1,789 shares on 11/11/2025 for $79,823.21 in gross proceeds. Shares outstanding are listed as 47,374,939.
AORT filed a Form 144 notice for a proposed sale under Rule 144 by security holder Jean F. Holloway. The filing lists 5,761 shares of common stock to be sold, with an aggregate market value of $264,189.66, through Fidelity Brokerage Services LLC on the NYSE, with an approximate sale date of 11/13/2025. Shares outstanding are shown as 47,374,939.
The shares to be sold were acquired via restricted stock vesting: 2,880 shares on 11/10/2025 and 2,881 shares on 11/11/2025, labeled as compensation. In the past three months, the filer reported sales of 10,000 shares on 08/25/2025 for $443,700.00, 2,960 shares on 11/10/2025 for $132,071.94, and 10,000 shares on 11/11/2025 for $461,800.00.
AORT disclosed a Form 144 notice for a proposed sale of 34,210 shares of common stock through Fidelity Brokerage Services LLC, with an aggregate market value $1,568,812.44. The filing lists an approximate sale date of 11/13/2025 on the NYSE.
The shares derive from recent restricted stock vesting: 17,105 shares on 11/10/2025 and 17,105 shares on 11/11/2025, each marked as Compensation. A recent activity section shows sales in the last three months by James Mackin of 12,500 shares on 08/15/2025 for $528,991.00 and 17,580 shares on 11/11/2025 for $784,400.26. Shares outstanding were 47,374,939 at the time referenced in the filing.
AORT filed a Form 144 for a proposed sale of up to 4,993 common shares, with an aggregate market value of $228,970.50. The approximate sale date is 11/13/2025, through Fidelity Brokerage Services LLC, on the NYSE.
The shares were acquired via restricted stock vesting as compensation: 2,496 shares on 11/10/2025 and 2,497 shares on 11/11/2025. In the past three months, the seller reported sales of 18,200 shares on 08/27/2025 for $801,211.32 and 2,566 shares on 11/11/2025 for $114,492.10. Shares outstanding were 47,374,939; this is a baseline figure, not the amount being offered.
John E. Davis filed a Form 144 notice to sell up to 6,563 shares of common stock, with an aggregate market value of
The securities were acquired via restricted stock vesting from the issuer on
Artivion (AORT): Schedule 13G/A Amendment No. 6—Macquarie Group Limited and affiliates reported beneficial ownership of 2,483,842 Artivion common shares, representing 5.26% of the class as of September 30, 2025. Macquarie Management Holdings Inc. and Macquarie Investment Management Business Trust report sole voting and dispositive power over 2,483,842 shares. The certification states the holdings were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control.
Artivion (AORT) insider activity: The company’s SVP and General Counsel reported multiple transactions. On 11/10/2025, 2,960 shares of common stock were sold at
The option exercised was originally granted with vesting at 33 1/3% per year beginning on 11/08/2023 and had an expiration date of 11/08/2029.